Document is current
Any future updates will be listed below
-
Authors
Sharma, Ashish https://orcid.org/0000-0002-8550-9791
Kumar, Nilesh https://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Regillo, Carl
Bandello, Francesco
Kuppermann, Baruch D.
- License Information
-
More Information
Article History
Received: 27 September 2022
Revised: 30 September 2022
Accepted: 7 October 2022
First Online: 17 October 2022
Competing interests
: AS: consultant for Novartis, Allergan, Bayer, and Intas. CR: consultant for Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Notal, Merck, Shire-Takeda, Adverum, Graybug, and Eyepoint and receives research support from Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Iveric, and Adverum. FB: consultant for Allergan, Bayer, Boehringer Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, ThromboGenics, and Zeiss. BDK: clinical research for Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, and ThromboGenics; consultant for Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, and Theravance Biopharma. NK: none. NP: none.
